Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
Big Pharma needs faster pipelines. Bristol Myers Squibb’s Hengrui pact shows why China’s R&D engine is becoming harder to ignore.
ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.
OJEMDA is already approved after relapse. FIREFLY-2 asks whether Servier can move targeted pLGG therapy earlier.
RLT demand is rising faster than supply chains can stretch. Novartis’ Texas buildout tests whether precision oncology can scale.
Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.
Samsung wants oncology optionality beyond manufacturing. Cartography’s Phase 1 T-cell engager puts platform biology under pressure.
Explore how CPTx’s targeted lipid nanoparticle platform could reshape CAR T therapy scalability and access. Read the full analysis now.
Arvinas Inc., with partner Pfizer Inc., has received U.S. Food and Drug Administration approval for VEPPANU, also known as vepdegestrant, for adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer after disease progression following at least one line of endocrine therapy. The approval gives the oncology market its […]
Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.